Gemcitabine plus nab‐paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study

Interstitial lung disease (ILD) is an adverse event associated with gemcitabine administration. Gemcitabine plus nab‐paclitaxel, which is now a first‐line chemotherapy regimen for pancreatic cancer (PC), may increase the risk of ILD; however, large‐scale clinical data on this are limited. Thus, this...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Kei, Michihata, Nobuaki, Hamada, Tsuyoshi, Jo, Taisuke, Matsui, Hiroki, Fushimi, Kiyohide, Nakai, Yousuke, Yasunaga, Hideo, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551588/
https://www.ncbi.nlm.nih.gov/pubmed/37547944
http://dx.doi.org/10.1111/cas.15910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551588/
https://www.ncbi.nlm.nih.gov/pubmed/37547944
http://dx.doi.org/10.1111/cas.15910

Ejemplares similares